Home › Obsessive-Compulsive Disorder › NCT04899687

Study of Dextromethorphan in OCD and Related Disorders

Fluoxetine/Dextromethorphan in Obsessive-Compulsive and Related Disorders: an Open-Label Crossover Pilot Study

Who can join

Ages 18 to 65 · All sexes

Inclusion Criteria:

* Diagnosis of obsessive-compulsive disorder (OCD), body dysmorphic disorder (BDD), illness anxiety disorder (IAD) or somatic symptom disorder (SSD)
* Living within California
* Capacity to provide informed consent

Exclusion Criteria:

* Current bipolar disorder or psychotic disorder
* Active moderate or severe substance use disorder, lifetime severe substance use disorder
* Pregnant or nursing women
* Use of prescribed psychotropic medications other than fluoxetine for 2 weeks prior to study start
* Having commenced OCD-targeted exposure and response-prevention (ExRP) psychotherapy within 2 months of study start

About the study

The purpose of the study is to assess the tolerability and efficacy of dextromethorphan in combination with fluoxetine for symptom relief in OCD and related disorders.

What is being tested

• Fluoxetine (drug)
• Dextromethorphan (drug)

Sponsor: Stanford University · Participants: 60 · Started: Jan 20, 2022

Contact the study team

• Alessa Gaeta, BA · Phone: 650 497 2578

Official record on ClinicalTrials.gov — NCT04899687

Locations in the U.S.

Conditions

• Obsessive-Compulsive Disorder

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.